Boc-Trp-OHCAS# 13139-14-5 |
- Cisplatin
Catalog No.:BCN1552
CAS No.:14283-03-5
- Z-VAD-FMK
Catalog No.:BCC1126
CAS No.:187389-52-2
- Z-WEHD-FMK
Catalog No.:BCC1139
CAS No.:210345-00-9
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- AZ 10417808
Catalog No.:BCC2356
CAS No.:331645-84-2
- Apoptosis Activator 2
Catalog No.:BCC2099
CAS No.:79183-19-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 13139-14-5 | SDF | Download SDF |
| PubChem ID | 7017899 | Appearance | Powder |
| Formula | C16H20N2O4 | M.Wt | 304.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate | ||
| SMILES | CC(C)(C)OC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)[O-] | ||
| Standard InChIKey | NFVNYBJCJGKVQK-ZDUSSCGKSA-M | ||
| Standard InChI | InChI=1S/C16H20N2O4/c1-16(2,3)22-15(21)18-13(14(19)20)8-10-9-17-12-7-5-4-6-11(10)12/h4-7,9,13,17H,8H2,1-3H3,(H,18,21)(H,19,20)/p-1/t13-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Boc-Trp-OH Dilution Calculator
Boc-Trp-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2852 mL | 16.4258 mL | 32.8515 mL | 65.703 mL | 82.1288 mL |
| 5 mM | 0.657 mL | 3.2852 mL | 6.5703 mL | 13.1406 mL | 16.4258 mL |
| 10 mM | 0.3285 mL | 1.6426 mL | 3.2852 mL | 6.5703 mL | 8.2129 mL |
| 50 mM | 0.0657 mL | 0.3285 mL | 0.657 mL | 1.3141 mL | 1.6426 mL |
| 100 mM | 0.0329 mL | 0.1643 mL | 0.3285 mL | 0.657 mL | 0.8213 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Boc-Trp-OH
- Teijin compound 1
Catalog No.:BCC6057
CAS No.:1313730-14-1
- Periplocin
Catalog No.:BCN2655
CAS No.:13137-64-9
- erythro-Guaiacylglycerol beta-threo-syringylglycerol ether
Catalog No.:BCN7333
CAS No.:1313434-74-0
- NVP-CGM097
Catalog No.:BCC5395
CAS No.:1313363-54-0
- Nystose
Catalog No.:BCN5397
CAS No.:13133-07-8
- threo Ifenprodil hemitartrate
Catalog No.:BCC7508
CAS No.:1312991-83-5
- Ro 8-4304 hydrochloride
Catalog No.:BCC7655
CAS No.:1312991-77-7
- Ro 25-6981 Maleate
Catalog No.:BCC4159
CAS No.:1312991-76-6
- Scutebarbatine Z
Catalog No.:BCN6991
CAS No.:1312716-28-1
- Scutebarbatine Y
Catalog No.:BCN6994
CAS No.:1312716-27-0
- Scutebarbatine X
Catalog No.:BCN6997
CAS No.:1312716-26-9
- Scutebarbatine W
Catalog No.:BCN7011
CAS No.:1312716-25-8
- Boc-Leu-OH.H2O
Catalog No.:BCC3408
CAS No.:13139-15-6
- Boc-Ile-OH.1/2H2O
Catalog No.:BCC3406
CAS No.:13139-16-7
- CBZ-Osu
Catalog No.:BCC2798
CAS No.:13139-17-8
- Hemopressin (human, mouse)
Catalog No.:BCC6065
CAS No.:1314035-51-2
- TC-N 22A
Catalog No.:BCC6150
CAS No.:1314140-00-5
- UNC669
Catalog No.:BCC3997
CAS No.:1314241-44-5
- Cercosporamide
Catalog No.:BCC2438
CAS No.:131436-22-1
- Amyloid Beta-Peptide (1-40) (human)
Catalog No.:BCC1045
CAS No.:131438-79-4
- TMP269
Catalog No.:BCC3993
CAS No.:1314890-29-3
- HG6-64-1
Catalog No.:BCC5459
CAS No.:1315329-43-1
- B-Raf inhibitor
Catalog No.:BCC1437
CAS No.:1315330-11-0
- NG25
Catalog No.:BCC1799
CAS No.:1315355-93-1
Imidazolo and tryptophan-imidazolo hybrid derived ureas/thioureas as potent bioactive agents - SAR and molecular modelling studies.[Pubmed:30684861]
Bioorg Chem. 2019 Jan 18;86:34-38.
Herein, we used an imidazole derivative (IMD) which showed promising antibacterial, antifungal and antioxidant properties in our earlier investigation. Prompted by this, we converted IMD to hydrazide (IMH) by hydrazinolysis which was derivatized to various ureas (3-7) and thioureas (8-12). On the other hand, IMH was conjugated to Boc-Trp-OH as it has been shown in the past that hybridization of two molecules produced promising biologically active compounds. Boc of the conjugate was removed and further converted into several urea (14-18) and thiourea (19-23) derivatives. All the title compounds so also the starting materials and intermediates were assessed for potential biological applications. The results showed that compounds 3, 4, 8, 9, 14, 15, 19 and 20 were excellent antioxidants as revealed by DPPH, DMPD and ABTS assays. Further, certain analogues like 5-7, 10-12, 16-18 and 21-23 were found to be potent antimicrobials against pathogenic bacteria and fungi whereas good anti-inflammatory activity was obtained for molecules 5-7, 10-12, 16-18 and 21-23. All together, derivatives of the conjugates have shown superior activity over non-conjugated compounds and the former have exhibited potent activity against standard drugs in all the assays. In a quest to understand the binding interactions of the compounds with active site of tyrosine kinase (PDB ID: 2HCK), glucosamine-6-phosphate (GlcN-6-P) synthase (PDB ID: 2VF5) and cyclooxygenase-2 (PDB ID: 1CX2) enzymes, the correlation studies were conducted using molecular modelling which showed good receptor binding interactions with several amino acids of the enzymes. Overall, the current investigation may be considered for the discovery of lead compound(s) for treating multiple disorder conditions using singular molecular entity.
